Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 13/20 | 0.48 |
| ▸ | PPARA | Q07869 | 4/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | FDPS | P14324 | 1/20 | 0.47 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21145509 | 0.88 | PPARD (0.51) | PPARDPPARAFFAR1 | |
| SCHEMBL8352315 | 0.81 | CYP19A1 (0.50) | PPARDPPARA | |
| SCHEMBL7847075 | 0.77 | FFAR1 (0.62) | PPARDPPARAFFAR1 | |
| SCHEMBL11923604 | 0.77 | CHRNB2 (0.49) | FDPSCHRNB2CHRNA4CHRNA7 | |
| SCHEMBL1470461 | 0.77 | FFAR1 (0.62) | PPARDPPARAFFAR1 | |
| SCHEMBL7845908 | 0.77 | FFAR1 (0.62) | PPARDPPARAFFAR1 | |
| Bromide SCHEMBL8113723 | 0.77 | CYP19A1 (0.49) | PPARDPPARA | |
| SCHEMBL19838561 | 0.76 | CHRNB2 (0.51) | FDPSCHRNB2CHRNA4CHRNA7 | |
| SCHEMBL3411465 | 0.74 | ESR1 (0.62) | PPARDPPARAFFAR1 | |
| Hydrochloric Acid SCHEMBL19839319 | 0.74 | CHRNB2 (0.50) | FDPSCHRNB2CHRNA4CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SUNOVION PHARMACEUTICALS INC. (US) | 2021-11-30 | — | — | US | disclosed |
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SUNOVION PHARMACEUTICALS INC. (US) | 2019-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190194163-A1 | DUAL NAV1.2/5HT2a INHIBITORS FOR TREATING CNS DISORDERS | SCN2A, HTR2A, HTR2C | PPARD 4644/4885PPARA 4643/4885FFAR1 3365/4885 |
| US-11186564-B2 | Dual NAV1.2/5HT2a inhibitors for treating CNS disorders | SCN2A, HTR2A, HTR2C | PPARD 4644/4885PPARA 4643/4885FFAR1 3365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.